Allogeneic marrow transplantation for chronic granulocytic leukemia
✍ Scribed by Speck, B. ;Gratwohl, A. ;Nissen, C. ;Osterwalder, B. ;M�ller, M. ;Bannert, P. ;M�ller, Hj. ;Jeannet, M.
- Publisher
- Springer-Verlag
- Year
- 1982
- Weight
- 314 KB
- Volume
- 45
- Category
- Article
- ISSN
- 1432-0584
No coin nor oath required. For personal study only.
✦ Synopsis
Six patients with Philadelphia-chromosome (Ph' +)-positive chronic granulocytic leukemia were transplanted from their HLA-identical siblings after conditioning with cyclophosphamide and 1'000 rad total body irradiation. All received cyclosporin-A for prophylaxis of Graft-versus-Host disease. All patients showed prompt engraftment and all are cytogenetically and clinically in complete remission. Two patients had transient mild signs of Graft-versus-Host-disease and one patient had unilateral facial nerve paresis of unknown origin. All are ambulatory and well 6-18 months (median 10 months) after transplantation.
📜 SIMILAR VOLUMES
A case of porphyria cutanea terda (PCT) occurring after bone marrow transplantation (BMT) is reported. A 43-year-oid male with chronic myelogenous leukemia received an human leukocyte antigen (HLA)-identical allogeneic transplantation with T-cell depleted marrow. Because of graft rejection, a second
Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow tran